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Abstract	(332/350)	33	
Background:	 Aspiration	 of	 subglottic	 secretions	 past	 the	 endotracheal	 tube	34	
(ETT)	 cuff	 is	 a	 prerequisite	 for	 developing	 ventilator-associated	 pneumonia	35	
(VAP).	Subglottic	secretion	drainage	(SSD)	ETTs	reduce	aspiration	of	subglottic	36	




a	 standard	 microbial	 suspension	 was	 added	 above	 inflated	 cuffs.	 After	 1	 h,	41	
aspiration	was	measured	and	ETTs	demonstrating	no	leakage	were	subjected	to	42	
rotational	 movement	 and	 evaluation	 over	 24	 h.	 Collected	 aspirated	 fluid	 was	43	
used	 to	 inoculate	 agar	media	 and	 incubated	 aerobically	 at	 37°C	 for	 24	 h.	 The	44	
aspiration	rate,	volume	and	number	of	microorganisms	that	leaked	past	the	cuff	45	
was	measured.	Experiments	were	repeated	(×10)	for	each	type	of	ETT,	with	new	46	
ETTs	 used	 for	 each	 repeat.	 Best	 performing	 ETTs	 were	 then	 tested	 in	 five	47	






PneuX	 ETT	 was	 statistically	 superior	 in	 reducing	 aspiration	 compared	 to	 the	54	
SealGuard	 (p<0.009),	 KimVent	 (p<0.002),	 TaperGuard	 (p<0.004),	 Lanz	55	
(p<0.001),	 ISIS	 (p<0.001),	 SACETT	 (p<0.001)	 and	 Soft	 Seal	 (p<0.001)	ETTs.	Of	56	
the	 4	 ETTs	 tested	 in	 differing	 cylinder	 sizes,	 the	 PneuX	 significantly	 reduced	57	
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aspiration	across	the	range	of	diameters	compared	to	the	SealGuard	(p<0.0001),	58	
TaperGuard	(p<0.0001)	and	KimVent	(p<0.0001)	ETTs.	59	
Conclusions:	ETTs	showed	 substantial	variation	 in	 fluid	aspiration,	 relating	 to	60	
cuff	material	and	design.	Variability	in	performance	was	likely	due	to	the	random	61	
manner	in	which	involutional	folds	form	in	the	inflated	ETT	cuff.	The	PneuX	ETT	62	
























the	 commonest	 infective	 nosocomial	 cause	 of	 mortality.	 In	 addition	 to	 the	86	






[4].	 However,	 the	 ETT	 subverts	 the	 patient’s	 normal	 pulmonary	 defence	93	
mechanisms,	 including	mucociliary	 clearance	 and	 the	 cough	 reflex	 [2,	 5].	 After	94	
intubation,	 the	 ETT,	 oropharyngeal	 surfaces	 and	 secretions	 rapidly	 become	95	
colonised	 with	 pathogenic	 bacteria	 [2,	 6].	 Gastric	 contents	 reflux	 into	 the	96	
oropharynx,	mix	with	these	secretions	[7]	and	accumulate	above	the	cuff.	If	the	97	
airway	 seal	 is	 compromised,	 aspiration	 of	 these	 secretions	 occurs	 [4].	 High	98	
bacterial	 load,	with	 chemical	 and	 enzymatic	 injury	 from	 gastric	 secretions,	 [3]	99	
can	 overwhelm	 pulmonary	 defences	 leading	 to	 microbial	 colonisation	 of	 the	100	
lower	 respiratory	 tract	 and	 VAP.	 One	 study	 showed	 that	 the	 bacteria	 in	101	
subglottic	 secretions	 were	 identical	 to	 the	 causative	 agents	 of	 VAP	 in	 70%	 of	102	
patients	 [8].	 Therefore,	 correctly	 achieving	 and	maintaining	 the	 airway	 seal	 is	103	
critical	in	preventing	VAP.	104	
Conventionally,	 ETTs	 have	 high-volume,	 low-pressure	 (HVLP)	 cuffs	 [9].	105	
The	fully	 inflated	HVLP	ETT	cuff	diameter	 is	 larger	than	the	adult	 trachea	[10],	106	
and	this	design	prevents	tracheal	mucosal	injury	by	allowing	the	pressure	within	107	
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the	 cuff	 to	 be	 equal	 to	 the	 tracheal	 wall	 pressure.	 Therefore,	 the	 cuff	 is	 only	108	
partially	 inflated,	 even	 when	 correct	 pressures	 are	 used.	 The	 excess	 material	109	
folds	 and	 causes	 involutions,	 causing	 channels	 to	 develop	 (figure	1)	 [9].	 These	110	
channels	 facilitate	aspiration	of	subglottic	secretions	into	the	 lungs.	 It	 is	widely	111	
accepted	 that	 aspiration	occurs	 for	 all	HVLP	ETTs	 to	 varying	degrees	 [11]	 and	112	




allow	 removal	 of	 subglottic	 fluids,	 thereby	 reducing	 the	 available	 volume	 of	117	
secretions	 entering	 the	 lungs.	 These	 subglottic	 secretion	 drainage	 (SSD)	 ETTs,	118	
have	 demonstrated	 lower	 VAP	 rates	 [12,	 18-24].	 Other	 ETTs	 use	 novel	 cuff	119	
materials	 to	 reduce	 the	number	 or	 size	 of	 channels	 [25],	 variations	 to	 the	 cuff	120	
shape,	 employ	 devices	 to	 continuously	 maintain	 cuff	 pressure	 [26]	 or	 employ	121	
antibacterial	coatings	[27].	However,	in	ETT	design,	manufacturers	must	account	122	
for	the	variability	in	the	size	and	shape	of	human	tracheas.	Tracheas	are	tapered	123	
and	 exhibit	 dimensional	 variability.	 The	 anterior-posterior	 (AP)	 tracheal	124	
diameter	 ranges	 between	 1.27-2.38	 cm	 for	 women	 and	 1.68-2.86	 cm	 for	men	125	
[28].	Selecting	the	correct	size	ETT	for	patients	is	subjective	and	determined	on	126	
the	 patient’s	 sex,	 height	 or	 weight	 [29].	 The	 wrong	 size	 can	 cause	 tracheal	127	
ischemia	(if	 too	 large)	or	 facilitate	aspiration	(if	 too	small)	[29].	A	recent	study	128	
identified	 an	 inverse	 relationship	 between	 tracheal	 size	 and	 body	mass	 index	129	
[30],	 highlighting	 potential	 difficulties	 in	 making	 accurate	 assessments.	130	
Therefore,	 ETTs	 need	 to	 account	 for	 anatomical	 variation	 and	 safeguard	 the	131	
trachea.		132	
	 	 	 7	









Test	 microorganisms	 were	 Pseudomonas	 aeruginosa	 ATCC	 15692,	142	
Staphylococcus	 aureus	 NCIB	 9518	 and	 Candida	 albicans	ATCC	 90027.	 Bacteria	143	
and	Candida	were	cultured	on	blood	or	Sabouraud’s	dextrose	agar,	respectively.	144	
Microorganisms	were	 subcultured	 and	 grown	 overnight	 (18	 h)	 in	 Tryptic	 Soy	145	
Broth	at	37°C.	Cells	were	harvested	by	centrifugation,	and	the	pellets	washed	in	146	




was	 used.	 To	 minimise	 variation	 in	 the	 number	 of	 viable	 cells	 between	151	










which	 the	 ETT	 was	 placed	 and	 the	 enteral	 syringe	 was	 used	 to	 capture	 the	161	
aspirated	 secretions.	 Seven	 ETTs	 (8.0	 mm)	 with	 design	 variations	 to	 prevent	162	








to	 the	 manufacturer’s	 instructions.	 If	 continuous	 cuff	 pressure	 monitors	 were	171	
recommended,	these	were	used	to	maintain	cuff	inflation	during	experiments.		172	
Four	ml	of	standardised	microbial	suspension	was	added	above	the	ETT	173	
cuff.	 The	 time	 taken	 for	 the	 fluid	 to	 leak	past	 the	ETT	 cuff	was	measured.	Any	174	
fluid	that	leaked	past	the	cuff	within	1	h,	was	collected	in	the	enteral	syringe	and	175	
this	was	recorded	as	a	 tube	 leak.	 In	cases	of	no	observed	fluid	 leak,	a	standard	176	
movement	test	(140°	axial	rotation,	to	mimic	oral	care	movements)	was	applied	177	
to	the	proximal	end	of	the	ETT	after	the	initial	1	h	period	at	0,	15,	30	and	45	min.	178	
If	 no	 leak	 was	 evident	 after	 the	 movement	 tests,	 the	 enteral	 syringe	 was	179	
disconnected	from	the	tip	of	the	20	ml	syringe	barrel,	aseptically	filled	with	4	ml	180	
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of	sterile	PBS	and	re-connected	to	the	tip	of	the	20	ml	syringe	barrel.	The	4	ml	181	
sterile	PBS	was	then	injected	into	the	20ml	syringe	below	the	inflated	ETT	cuff.	182	












The	4	 ‘best	 performing’	 ETTs	 from	 the	microbiological	 study	were	 analysed	 in	195	
these	 experiments.	Model	 tracheas	were	 developed	 using	 rigid	 glass	 cylinders,	196	
with	 internal	 diameters	 of	 1.6,	 1.8,	 2.2	 and	 2.4	 cm	 (Dabble	 Labs	UK,	Kent	UK)	197	
(figure	2b).	For	the	2.0	cm	sized	‘trachea’	diameter,	the	syringe	model	described	198	
above	(and	shown	in	figure	2a)	was	utilised.	ETTs	were	positioned	vertically	and	199	




standard	 movement	 test	 was	 applied	 to	 the	 proximal	 ETT	 as	 previously	204	
described.	Experiments	were	repeated	(×10)	for	each	tracheal	size.	205	







Results	 were	 analysed	 using	 ANOVA	 analysis	 and	 a	 Tukey	 multiple	212	
comparison	of	the	means.	This	test	compared	the	overall	performance	of	all	ETTs	213	
in	 preventing	 aspiration	 of	 microbial	 fluids	 past	 the	 cuff	 and	 compared	 the	214	





Results	 were	 analysed	 using	 non-parametric	 statistical	 analysis	 for	220	






Aspiration	was	 expressed	as	 total	 cfu/min	and	volume	of	 fluid	 leaked	past	 the	227	
cuff.	 With	 the	 exception	 of	 the	 PneuX	 ETT,	 all	 ETTs	 demonstrated	 leakage	 of	228	
microorganisms	past	the	cuff.	The	Portex	Soft	Seal,	Lanz,	ISIS	and	SACETT	ETTs	229	
leaked	 4	 ml	 of	 microbial	 fluid	 on	 all	 occasions	 (between	 <5	 min	 –	 1	 h).	 The	230	
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SealGuard,	KimVent	and	TaperGuard	ETTs	leaked	on	some	occasions	and	these	231	
were	 analysed	 in	 the	movement	 test.	 Once	 rotation	was	 applied,	 aspiration	 of	232	
bacterial	 fluid	 occurred	 with	 all	 TaperGuard	 and	 KimVent	 ETTs	 and	 on	 some	233	
occasions	 with	 the	 SealGuard	 ETT.	 The	 PneuX	 ETT	 was	 the	 only	 ETT	 that	234	




studied	ETTs	when	comparing	microbial	 fluid	 leakage	 (p<0.00001).	The	PneuX	239	
ETT	did	not	 allow	aspiration	 in	 any	 experiment	 and	 therefore,	 non-parametric	240	
statistical	 analysis	 for	 repeated	measures	 was	 used	 to	 compare	 all	 other	 ETT	241	
results	 against	 the	 PneuX	 ETT.	 The	 PneuX	 ETT	 demonstrated	 significantly	242	
reduced	 aspiration	 compared	 to	 the	 SealGuard	 (p<0.009),	 KimVent	 (p<0.002),	243	
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different	 sized	 ‘trachea	 models’.	 Aspiration	 was	 expressed	 as	 volume	 of	 fluid	256	
leaked	past	the	cuff.	257	
With	 the	exception	of	 the	PneuX	ETT,	 all	ETTs	demonstrated	 leakage	of	258	
fluid	past	the	cuff	across	the	different	trachea	sizes.	Of	the	trachea	sizes	tested,	259	
the	‘best’	diameters	for	the	SealGuard	and	TaperGuard	ETTs	were	the	2.0	and	2.2	260	
cm,	 and	 for	 the	 KimVent	 ETT	 it	 was	 2.4	 cm	 (figure	 5).	 Since	 the	 PneuX	 ETT	261	
demonstrated	 no	 aspiration	 of	 fluid	 past	 the	 cuff	 for	 any	 tracheal	 size	 non-262	
parametric	statistical	analysis	for	repeated	measures	was	again	used	to	compare	263	
all	 other	 ETT	 results	 against	 the	 PneuX	 ETT.	 The	 PneuX	 ETT	 was	 found	 to	264	





Aspiration	 of	 pathogenic	 subglottic	 secretions	 past	 the	 ETT	 cuff	 is	 a	270	
recognised	 risk	 factor	 for	 VAP	 [9].	 All	 HVLP	ETT	 cuffs	 form	 channels	 allowing	271	
aspiration	of	subglottic	secretions	[11].	Manufacturers	have	redesigned	aspects	272	
of	 their	 ETTs	 to	 limit	 this.	 These	 studies	 compared	 8	 ETTs	 in	 preventing	273	





the	 cuff.	 Only	 the	 PneuX	 ETT	 (low	 volume,	 low	 pressure	 (LVLP)	 cuff),	279	
consistently	prevented	aspiration	of	fluid	under	all	test	conditions	(figure	3	and	280	
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5,	 6).	Aspiration	of	microorganisms	occurred	 in	 all	 experiments	with	 the	Lanz,	281	
ISIS,	SACETT	and	Soft	Seal	ETTs.	Results	were	variable	in	terms	of	leaked	volume,	282	
rate	 of	 leakage	 and	microbial	 aspiration.	With	 the	 SealGuard,	 TaperGuard	 and	283	
the	KimVent	ETTs,	 some	 tubes	permitted	aspiration	almost	 immediately,	 some	284	
progressed	 to	 the	movement	 study	 and	 some	 did	 not	 leak	 after	manipulation.	285	
Similar	 results	were	 seen	 for	 the	 ‘trachea	 size’	 study,	where	 performance	was	286	
also	 variable.	 The	 variation	within	 the	 same	 type	 of	 ETTs,	 likely	 relates	 to	 the	287	
manner	in	which	folds	develop	within	the	cuff	during	inflation,	which	appears	to	288	
be	random	(figure	6).	This	was	highlighted	in	the	movement	study,	where	upon	289	
manipulation,	 the	 folds	 in	 the	cuffs	 that	had	originally	 formed	 in	such	a	way	to	290	
prevent	leakage	in	the	static	model	moved,	enabling	a	fluid	pathway	to	develop	291	
thus	 allowing	 leakage	 of	 fluid.	 The	 variability	 in	 performance	 evident	 in	 these	292	
studies	 could	 lead	 to	unpredictable	 results	 in	clinical	practice.	A	 recent	 clinical	293	
study	 reported	 that	 the	 KimVent,	 TaperGuard	 and	 SealGuard	 ETTs	 were	 not	294	
superior	 to	 a	 standard	 ETT	 in	 preventing	 tracheal	 colonisation	 or	 VAP	 [17].	295	
Indeed,	our	results	in	this	in	vitro	model	would	have	predicted	that	in	a	clinical	296	
trial	[17],	where	expected	duration	of	ventilation	was	greater	than	48	hours	the	297	
KimVent,	 TaperGuard	 and	 SealGuard	 ETTs	 would	 have	 not	 have	 performed	298	
better	than	a	standard	ETT	in	preventing	VAP.	299	





benefit	 over	 cylindrical	 cuffs	 [14,	 33].	 In	 this	 study	 the	 TaperGuard	 and	305	
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SealGuard	 ETTs	 performed	 better	 than	 most	 HVLP	 ETTs.	 However,	 both	 the	306	
tapered	 ISIS	 and	 SACETT	 ETT	 cuffs	 made	 of	 polyvinylchloride,	 permitted	307	




to	 afford	greater	protection,	 as	 this	was	 the	best	performing	HVLP	ETT	 in	 this	312	
study.		313	
Studies	 show	 that	 maintaining	 cuff	 pressure	 correctly	 reduces	 the	314	
incidence	of	VAP	[34].	In	this	study	the	Lanz	and	SACETT	ETTs	were	used	with	315	
their	recommended	cuff	pressure	monitors,	however	their	performance	was	not	316	
superior	 to	 the	 Soft	 Seal	 ETT.	 Maintaining	 correct	 cuff	 pressure	 is	 important	317	
however	 this	 study	showed	 that	 the	properties	of	 the	ETT	cuff	may	be	equally	318	
important	in	preventing	aspiration.		319	
The	PneuX	ETT	consistently	prevented	aspiration	in	all	experiments.	The	320	
LVLP	 cuff	 of	 the	 PneuX	 ETT	 is	 made	 of	 highly	 elastic	 silicone	 and	 uniformly	321	
inflates	 until	 the	 correct	 tracheal	 wall	 pressure	 is	 achieved	 at	 the	 required	322	
tracheal	circumference,	hence,	the	cuff	does	not	develop	folds	(figure	6)	[35].	The	323	
PneuX	ETT	used	 a	 tracheal	 seal	monitor,	 designed	 to	maintain	 the	pressure	of	324	
the	silicone	cuff	at	the	appropriate	pressure	at	all	times,	even	during	movement	325	
[35]	and	 this	was	demonstrated	 in	 this	 study.	Our	results	 replicate	previous	 in	326	
vitro	studies	which	demonstrate	no	leakage	past	the	cuff	for	the	PneuX	ETT	and	327	
superior	 performance	 when	 compared	 to	 other	 ETT	 examined	 [10,	 36].	 Our	328	
findings	 are	 also	 supported	 by	 a	 recent	 publication	 by	 Chenelle	 et	 al.,	 which	329	
demonstrated	leakage	in	a	different	bench	model	[37].	In	their	study,	Chenelle	et	330	
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al.,	 showed	 leakage	occurred	with	 all	HVLP	 cuffs	 tested	 and	was	prevented	by	331	
the	PneuX	cuff	[37].	Our	study	confirms	and	builds	on	this	data,	by	testing	all	the	332	
SSD	ETT	currently	available	and	also	examines	the	quantification	of	the	bacterial	333	
load	which	 the	 lungs	may	be	exposed	 to.	Commonly,	 in	vitro	studies	have	used	334	
water	to	demonstrate	leakage	past	the	cuff	[10,	12,	32,	37].	Our	study	is	novel	in	335	




microbial	 solution	 was	 equivalent	 to	 ca.	 107	 cells/ml.	 Although	 higher	 than	340	
typically	 encountered	 clinically,	 this	 served	 to	 enhance	 discrimination	 and	341	
sensitivity	 of	 the	 experiments.	 In	 experiments	where	no	 visible	 aspiration	was	342	
seen,	 the	space	below	 the	cuff	was	 irrigated	 to	determine	whether	micro-leaks	343	
occurred	and	in	this	study,	no	microaspiration	of	microorganisms	were	detected.		344	
In	 initial	 experiments,	 the	 correlation	 between	 cfu/min	 and	 volume	345	
leaked	past	the	cuff	was	demonstrated	and	volume	of	fluid	was	therefore	used	as	346	
a	surrogate	for	bacterial	load	in	the	‘trachea	size’	study.	It	was	important	to	test	347	
ETTs	 across	 a	 range	 of	 trachea	 sizes,	 due	 to	 the	 considerable	 anatomical	348	
variability	 [28].	One	may	argue	 that	 clinicians	would	not	use	 a	 size	8.0	ETT	 in	349	
patients	with	1.6	or	2.4	cm	tracheas.	However,	patients	are	not	routinely	scanned	350	
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Many	clinical	trials	with	novel	ETTs	aimed	at	preventing	VAP	often	show	355	
disappointing	results.	These	are	costly,	time	consuming	and	often	fail	to	replicate	356	
in	vitro	results	 [39].	 Our	 study	 tested	 8	 ETTs	 across	 a	 range	 of	 ‘trachea’	 sizes,	357	








Prevention	of	 aspiration	past	 the	ETT	 cuff	 is	 a	 prerequisite	 for	 averting	366	
VAP.	In	these	investigations,	variation	in	the	efficacy	of	HVLP	ETTs	was	apparent	367	
and	 likely	 due	 to	 the	 random	manner	 in	 which	 folds	 develop	 in	 the	 cuff.	 The	368	
PneuX	ETT	was	the	only	ETT	to	consistently	prevent	aspiration	past	the	cuff	 in	369	
all	 experiments.	 The	 PneuX	 ETT	 should	 be	 further	 evaluated	 in	 patients	 using	370	
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of	 fluid	past	 the	cuff.	Despite	 inflating	 the	ETT	cuff	 to	 the	correct	 tracheal	wall	561	
pressure,	 it	 is	 only	 partially	 inflated	 with	 excess	 material	 folding	 and	 causing	562	
involutions.	 The	 blue	 dye	 highlights	 the	 formation	 of	 channels,	 which	 allow	563	
leakage	of	subglottic	fluid	into	the	lungs	overhead	view	(A)	and	a	lateral	view	(B).	564	
	565	
Figure	 2a:	 The	 in	vitro	 trachea	model	 used	 in	 the	 aspiration	 of	microbial	 fluid	566	
study.	The	20	ml	syringe	was	connected	to	the	10	ml	enteral	syringe	via	the	tip.	567	
The	 endotracheal	 tube	was	 placed	 in	 the	 20	ml	 syringe.	 Fluid	 leaking	 past	 the	568	
cuff	 was	 collected	 aseptically	 in	 the	 enteral	 syringe.	 Figure	 2b:	 the	 in	 vitro	569	
trachea	model	used	 in	 the	 range	of	 tracheas	 study.	The	endotracheal	 tube	was	570	





units	 aspirated	past	 the	 cuff	 for	 each	ETT.	 3b:	 Volume	of	 fluid	 leaked	past	 the	576	





Figure	4:	Correlation	between	volume	 leaked	past	 the	 cuff	 and	number	of	CFU	581	
count.	Correlation	co-efficient	=	0.826,	p<0.0001.		582	
Figure	 5:	 Effect	 of	 tracheal	 size	 (1.6,	 1.8,	 2.0,	 2.2	 and	 2.4	 cm)	 on	 aspiration	583	
(volume	of	fluid)	past	the	cuff	per	hour.	The	PneuX	ETT	was	the	only	tube	that	584	
prevented	 the	aspiration	of	 fluid	at	each	 tracheal	size.	Variability	of	 the	results	585	
was	evident	for	each	HVLP	ETT.		586	
Figure	6:	Aspiration	of	 fluid	(blue	dye)	past	 the	cuff	and	differences	 in	channel	587	
formation	seen	with	each	ETT	cuff.	(A)	Portex	Soft	Seal	®	Cuff	Tracheal	Tube,	(B)	588	
The	 VennerTM	 PneuX	 P.Y.	 TM	 ETT	 (C)	 MallinckrodtTM	 SealGuardTM	 Evac	589	
Endotracheal	 Tube,	 (D)	 KimVentTM	 MICROCUFF	 Subglottic	 Suctioning	590	
Endotracheal	 Tube,	 (E)	 MallinckrodtTM	 TaperguradTM	 Evac	 Oral	 Endotracheal	591	
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